ZBTB17 and early-onset autosomal dominant Alzheimer disease: The above results suggest that knocking down NKRF or knocking out ZBTB17 can inhibit the progression of Alzheimer's disease (AD), with the most significant inhibition of AD progression achieved by altering the expression of both factors.